Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 3/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10126526 | 0.84 | MAPT (0.30) | MAPT | |
| SCHEMBL19634902 | 0.77 | MAPT (0.67) | MAPTHTTALDH1A1MEN1MAPK1 | |
| SCHEMBL10126484 | 0.73 | BCHE (0.44) | CYP1A2 | |
| SCHEMBL10126625 | 0.72 | MAPT (0.43) | MAPTHTTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11939297 | 0.72 | MAPT (0.40) | MAPTHTTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10126523 | 0.68 | MAPT (0.53) | MAPTHTTALDH1A1MEN1MAPK1 | |
| SCHEMBL10111160 | 0.66 | ALDH1A1 (0.48) | MAPTCYP3A4ALDH1A1MEN1MAPK1 | |
| SCHEMBL10126879 | 0.66 | THRB (0.52) | MAPTHTTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10416186 | 0.66 | ALDH1A1 (0.53) | MAPTHTTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7398270 | 0.66 | MAPT (0.73) | MAPTHTTCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120168693-A1 | SILVER-(CONJUGATED COMPOUND) COMPOSITE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120032121-A1 | METALLIC COMPOSITE AND COMPOSITION THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120032121-A1 | METALLIC COMPOSITE AND COMPOSITION THEREOF | CDH1, EPCAM, CD4 | MAPT 297/4885HTT 3725/4885CYP1A2 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.